Traphagen Investment Advisors LLC Takes $31,000 Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Traphagen Investment Advisors LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, Holdings Channel reports. The fund purchased 30,500 shares of the biotechnology company’s stock, valued at approximately $31,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. US Bancorp DE bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $40,000. XTX Topco Ltd lifted its holdings in CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after buying an additional 48,033 shares during the period. Forefront Analytics LLC increased its stake in shares of CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares during the period. Cubist Systematic Strategies LLC lifted its stake in CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 40,309 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of CytomX Therapeutics during the 3rd quarter valued at about $104,000. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Up 3.7 %

CytomX Therapeutics stock opened at $0.87 on Wednesday. The stock’s 50 day moving average is $1.03 and its 200 day moving average is $1.15. The company has a market capitalization of $68.18 million, a P/E ratio of 5.12 and a beta of 1.03. CytomX Therapeutics, Inc. has a twelve month low of $0.79 and a twelve month high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million during the quarter, compared to analyst estimates of $18.92 million. During the same quarter in the previous year, the firm earned $0.04 EPS. As a group, equities analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.77.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.